Clinical trials
Active, not recruiting Phase 2 trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
146 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 15 |
| 2019 | 15 |
| 2020 | 12 |
| 2021 | 15 |
| 2022 | 22 |
| 2023 | 16 |
| 2024 | 24 |
| 2025 | 14 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 146 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 11 |
| The Netherlands Cancer Institute | 11 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 9 |
| AstraZeneca | 8 |
| Janssen Research & Development, LLC | 6 |
| European Organisation for Research and Treatment of Cancer - EORTC | 5 |
| Merck Sharp & Dohme LLC | 5 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 4 |
| GlaxoSmithKline | 4 |
| Borstkanker Onderzoek Groep | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 12 |
| Neoplasms | 10 |
| Breast Neoplasms | 6 |
| Colorectal Neoplasms | 6 |
| Lung Diseases, Interstitial | 4 |
| Neoplasm Metastasis | 4 |
| Pancreatic Neoplasms | 4 |
| Adenocarcinoma | 3 |
| Colitis, Ulcerative | 3 |
| Crohn Disease | 3 |
Trials
Showing 1 to 25 of 146. Each trial links to its page on Pharma Observatory.
46 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.